IDX899: Phase IIb started

GlaxoSmithKline began the international Phase IIb SONNET trial to compare blinded once-daily 100 and 200 mg GSK2248761 vs. open-label etravirine for 48 weeks in 150 antiretroviral therapy-experienced patients with NNRTI resistance. The trial start triggers a $20 million milestone payment to Idenix from ViiV Healthcare, a JV formed by GSK and Pfizer Inc. (NYSE:PFE, New York, N.Y.) last year to develop and commercialize compounds to treat HIV. GSK has an exclusive, worldwide license to develop GSK2248761 under a 2009 deal with Idenix (see BioCentury, Feb. 9, 2009 & Nov. 9, 2009). Idenix is eligible for up to $390 million in additional milestones, plus double-digit tiered royalties. ...